
Loading, please wait...

Loading, please wait...

The long-term use of benzodiazepines (BZDs) remains a significant challenge in modern clinical practice. While effective for short-term relief of anxiety and insomnia, prolonged usage increases the risk of falls, cognitive impairment, and dependency. Consequently, implementing effective benzodiazepine deprescribing strategies has become a priority for primary healthcare professionals. Recent evidence emphasizes the transition from simple protocols to multi-faceted, patient-centered approaches that address behavioral barriers.
A comprehensive overview of systematic reviews highlights that multifaceted interventions are the most successful in primary care settings. These strategies often integrate several components to address both the physical and psychological aspects of drug dependency. Research indicates that gradual dose reduction remains the cornerstone of clinical practice, utilized in approximately 71% of successful interventions. Furthermore, patient education (50%) and cognitive-behavioral therapy (43%) significantly improve success rates compared to tapering alone.
Pharmacist-led interventions also demonstrate high efficacy in benzodiazepine deprescribing strategies. By conducting thorough medication reviews and providing structured guidance, pharmacists help bridge the gap between initial prescription and successful cessation. In addition, audit-and-feedback mechanisms allow clinicians to monitor their own prescribing patterns and adjust their approach based on real-world data. These combined efforts create a supportive environment for patients navigating the withdrawal process.
Despite the availability of evidence-based benzodiazepine deprescribing strategies, several barriers persist. Patients often fear withdrawal symptoms or the return of underlying conditions like insomnia. On the provider side, resistance may stem from insufficient training, low self-efficacy, or limited consultation time. To facilitate change, clinics should adopt shared decision-making models. Providing structured education and setting clear, achievable goals can empower patients and reduce anxiety during the tapering phase. Moreover, incorporating behavioral frameworks can enhance the sustainability of these interventions.
Gradual dose reduction is considered the most effective method. Clinical experts often recommend reducing the dose by 10% to 25% every two weeks. This slow pace helps minimize withdrawal symptoms and allows the patient's system to adjust safely to lower levels of the medication.
Pharmacists play a critical role by conducting medication reviews and providing specific patient education materials. They can identify inappropriate use early and offer technical support to physicians during the complex tapering process, which ensures higher patient safety.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.
References
1. Duarte-Anselmi G et al. De-implementing inappropriate benzodiazepine prescribing in primary care: an overview of systematic reviews informed by behavioral frameworks. Implement Sci Commun. 2026 Feb 21. doi: 10.1186/s43058-026-00879-1. PMID: 41721449.
2. Pottie K et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.
3. Zeraatkar D et al. Comparative effectiveness of interventions to facilitate deprescription of benzodiazepines and other sedative hypnotics: systematic review and meta-analysis. BMJ 2025;389:e081336.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A review of systematic evidence on multifaceted interventions, like education and gradual tapering, to reduce inappropriate benzodiazepine use in primary ca...
8 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today